Itraconazole toxicity monitoring in dogs treated for blastomycosis centers on serial liver enzyme surveillance and therapeutic drug monitoring, with compounded formulations requiring particular scrutiny.
Hepatotoxicity is the primary adverse effect to monitor. Elevated alanine aminotransferase (ALT) activity occurs in 26% of itraconazole-treated dogs with blastomycosis.Journal of Vete… Skin lesions with crusting, inflammation, and discharge are also a recognized adverse effect — in one reported case, these developed after 3 months of itraconazole at 5 mg/kg PO q24h and resolved after drug discontinuation.Journal of the… Itraconazole should be administered with food to maximize absorption; concurrent antacids, H2-blockers, and cholinergics are contraindicated.MSD Vet Manuals
Therapeutic drug monitoring is recommended for all dogs on itraconazole, regardless of formulation. The therapeutic target extrapolated from human data is a trough serum itraconazole concentration of at least 0.5–1.0 µg/mL by HPLC.Journal of Vete… Compounded itraconazole (bulk powder) produces a mean serum concentration of only 0.5 µg/mL, and 95.2% of dogs receiving it have subtherapeutic concentrations below 1.0 µg/mL — compounded formulations should be avoided.Journal of the… Generic pelletized itraconazole produces a mean concentration of 8.3 µg/mL and brand-name produces 6.5 µg/mL, with no statistically significant difference between these two.Journal of the… However, 12.5% of dogs on generic and 12.1% on brand-name still achieve subtherapeutic levels, and 37.5% on generic and 24% on brand-name reach potentially toxic concentrations above 10 µg/mL — making individual monitoring clinically important in all cases.Journal of the…
Liver enzyme monitoring should accompany each recheck visit. The veterinary literature does not specify a fixed monitoring interval for ALT in blastomycosis-treated dogs, but urine Blastomyces antigen testing is performed monthly during treatment in published protocols, providing a natural cadence for concurrent biochemistry.Journal of Vete… If skin lesions consistent with itraconazole reaction develop, the drug can be temporarily discontinued and reintroduced at a reduced dose of 2.5 mg/kg PO q24h for 30 days before returning to 5 mg/kg PO q24h — skin lesions did not recur with this rechallenge approach in one reported case.Journal of the…
| Parameter | Target / Threshold | Action if Abnormal |
|---|---|---|
| Serum itraconazole trough | ≥0.5–1.0 µg/mL (HPLC)Journal of Vete… | Increase dose or switch formulation if subtherapeutic |
| Serum itraconazole trough | >10 µg/mLJournal of the… | Dose reduction; monitor for hepatotoxicity |
| ALT activity | Elevated above reference | Weigh risk/benefit; consider dose reduction or switch to fluconazole |
| Skin lesions (crusting, discharge) | Clinical finding | Discontinue; rechallenge at 2.5 mg/kg q24h × 30 days, then return to 5 mg/kgJournal of the… |
| Formulation | Compounded bulk powder | Switch to generic pelletized or brand-name immediatelyJournal of the… |
Would you like guidance on switching to fluconazole if itraconazole toxicity requires discontinuation?